Objective. To present a patient with metastatic pros tate cancer who has experienced an extended re sponse to the withdrawal of flutamide and the con comitant initiation of aminoglutethimide.
Case Summary. A 73-year-old male was diagnosed with advanced metastatic prostate cancer. He received treatment with suramin, leuprolide, and flutamide. After progressing on this regimen his flutamide was discon tinued and aminoglutethimide was initiated. His re sponse to this treatment has reached almost 3 years, with no evidence of progression.
Discussion. The response to the withdrawal of flutamide is thought to arise from a mutated androgen receptor that recognizes hydroxyflutamide, the active metabolites of flutamide, as an agonist. The receptor continues to recognize endogenous steroids as agonists. The addition of the adrenal steroid synthesis inhibitor, aminoglutethimide may play a role in enhancing this response phenomenon.
Conclusions. This patient is progression free for approximately 3 years following the withdrawal of flutamide. This maneuver has been found to have activity in a subset of patients who have been treated for metastatic prostate cancer with combined andro gen blockade.
Crawford EDChallenges in the management of prostate cancer. Br J Urology . 1992;70:33-38.
2.
Scher HI, Kelly WKFlutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol.1993;11: 1566-1572.
3.
Figg WD, Sartor O., Cooper M., et al. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med.1995;98:412- 414.
4.
Sartor O., Cooper M., Weinberger M., et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst. 1994;86:222-227.
5.
Figg WD, McCall NA, Reed E., Sartor O.The in vitro response of four antisteroid receptor agents on the hormone-responsive prostate cancer cell line LNCaP. Oncol Reports.1995; 2:1- 4.
6.
Veldscholte J., Ris-Stalpers C., Kuiper Ggjm, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun.1990;173:534-540.
7.
Labrie F., Belanger A., Simard J., Labrie C., Dupont A.Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer. 1993;71 (suppl):1059-1067.
